%0 Journal Article
%T Evaluation of coronary microvascular dysfunction using magnetocardiography: A new application to an old technology.
%A Ashokprabhu N
%A Ziada K
%A Daher E
%A Cho L
%A Schmidt CW
%A Roca Y
%A Palmer C
%A Kaur S
%A Henry TD
%A Pepine CJ
%A Quesada O
%J Am Heart J Plus
%V 44
%N 0
%D 2024 Aug
%M 39108843
暂无%R 10.1016/j.ahjo.2024.100424
%X <B>UNASSIGNED: </B>In patients with angina and non-obstructive coronary artery disease (ANOCA), diagnosis of coronary microvascular dysfunction (CMD) remains an unmet need. Magnetocardiography (MCG), is a rest-based, non-invasive scan that can detect weak electrophysiological changes that occur at the early phase of ischemia.<BR><B>UNASSIGNED: </B>This study assessed the ability of MCG to detect CMD in ANOCA patients as compared to reference standard, invasive coronary flow reserve (CFR).<BR><B>UNASSIGNED: </B>Patients with ANOCA and invasive coronary physiologic assessment using intracoronary flow measurements with Doppler and thermodilution methods were enrolled. CMD was defined dichotomously as an invasive CFR < 2.0 by Doppler or thermodilution assessment. Noninvasive 36-channel 90-s MCG scan was performed and quantitative assessment of four distinct MCG features was completed. We evaluated the diagnostic performance of 2 or more abnormal MCG features to detect CMD in the overall cohort and performed a subgroup analysis in the subset of patients with Doppler CFR assessment.<BR><B>UNASSIGNED: </B>Among 79 ANOCA patients, 25 were CMD positive and 54 patients were CMD negative by CFR. Using invasive CFR as reference, MCG had an ROC AUC of 0.66 with a sensitivity of 68 % and specificity of 65 % for the detection of CMD. In the subgroup with Doppler CFR assessment, MCG had an ROC AUC of 0.76 with a sensitivity of 75 % and specificity of 77 %.<BR><B>UNASSIGNED: </B>In ANOCA patients, MCG demonstrates the ability to detect CMD using a 90-second non-invasive scan without the need for an intravenous stressor or ionizing radiation. Further investigations are needed to validate an MCG-based diagnostic pathway for CMD.